Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2.
Augmentation of natural killer (NK) cell activity has been observed after the single administration of a wide variety of biological response modifiers (BRM); however, multiple injections of BRM have resulted in hyporesponsiveness to NK augmentation in both preclinical and clinical studies. In these studies, hyporesponsiveness to augmentation of NK cell activity occurred after multiple injections of interferon (IFN recombinant human IFN-alpha A/D and recombinant IFN-gamma) and interleukin 2 and was found to be systemic (lungs, liver, blood, and spleen). In contrast, hyporesponsiveness to augmentation by multiple injections of maleicanhydride divinyl ether (MVE-2) or Propionibacterium acnes was limited to the spleen and peripheral blood lymphocytes, with continued augmentation of NK cell activity in the peritoneum, lungs, and liver. Despite the hyporesponsiveness to augmentation of NK activity by multiple IFN injections, NK activity could still be augmented by a single injection of another BRM. The NK cell hyporesponsiveness induced in the spleen by MVE-2 was also reversed by a single administration of IFN or polyinosinic-polycytidylic and poly-L-lysine solubilized by carboxymethyl cellulose but not by OK-432 or P. acnes. These results demonstrate that the nature of the hyporesponsiveness to NK augmentation, which is induced by multiple treatments with BRM, varies with the type of agent. The noncytokine BRM that were studied induced hyporesponsiveness only in specific lymphoid compartments but not in major nonlymphoid organs, whereas cytokine BRM induced a systemic hyporesponsiveness. The hyporesponsive state induced by the different types of BRM, also varied in regard to the pattern of susceptibility to augmentation of NK activity by unrelated BRM.
J E
JE
Talmadge
R B
RB
Herberman
M A
MA
Chirigos
A E
AE
Maluish
M A
MA
Schneider
J S
JS
Adams
H
H
Philips
G B
GB
Thurman
L
L
Varesio
C
C
Long
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D001688:Biological Products / Q000494:pharmacology; D002266:Carboxymethylcellulose Sodium / Q000008:administration & dosage / Q000031:analogs & derivatives; D016207:Cytokines; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007372:Interferons / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage*; D007694:Killer Cells, Natural / Q000276:immunology*; D008099:Liver / Q000276:immunology; D008168:Lung / Q000276:immunology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009928:Organ Specificity; D011070:Poly I-C / Q000008:administration & dosage; D011107:Polylysine / Q000008:administration & dosage / Q000031:analogs & derivatives; D011713:Pyran Copolymer / Q000008:administration & dosage; D013154:Spleen / Q000276:immunology
D000276:Adjuvants, Immunologic; D001688:Biological Products; D016207:Cytokines; D007376:Interleukin-2; D011107:Polylysine; D011713:Pyran Copolymer; C019531:poly ICLC; D007372:Interferons; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C